ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 226

Comparing the Burden of Illness of Patients with Tophaceous and Non-Tophaceous Gout in France, Germany, Italy, Spain, UK, and USA

Puja Khanna1, Eskinder Tafesse2, Scott Baumgartner3, Anna Walker4 and Robert Morlock3, 1Rheumatology, University of Michigan, Ann Arbor, MI, 2AstraZeneca Pharmaceuticals, Gaithersburg, MD, 3Ardea Biosciences, Inc., San Diego, CA, 4AstraZeneca Pharmaceuticals, Luton, United Kingdom

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: gout, hyperuricemia and tophaceous gout

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Metabolic and Crystal Arthropathies - Poster I: Clinical Practice

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Gout is the most common form of inflammatory arthritis, with an increasing prevalence worldwide. ACR management guidelines recommend a target serum uric acid (sUA) <6 mg/dL, or <5 mg/dL in patients with tophaceous disease. Patients with significant crystal burden (tophaceous gout) are considered to have higher humanistic and economic burden of illness. These analyses describe patient and treatment characteristics and resource utilization in gout patients with and without tophi.

Methods:  Data were assessed from physician surveys and in-depth patient chart audits in France, Germany, Italy, Spain, UK, and USA. Flares, organ/joint damage and tophi were extracted from clinical charts. Type/dose gout treatment, time on current therapy, physician type, and patient sociodemographic factors were identified. Demographic characteristics and comorbidities, sUA levels, and use of colchicine for acute flares during the 12-month study period were compared using chi-square or Fisher’s exact tests.

Results:  Of the 2505 patients identified, 612 (24. 43%) had physician-confirmed tophaceous gout and 1893 (75.57%) had non-tophaceous gout. Patients with tophi were older (61.6 vs 57.4 years), had gout for a slightly longer period (2.8 vs 2.4 years), reported more flares (3.2 vs 1.7 per year) over the last 12 months, and were more likely to have higher sUA (12-month mean 7.80 vs 7.34 mg/dL) (all p<0.001). Levels of comorbidities were significantly higher in patients with tophi including cardiovascular disease, chronic obstructive pulmonary disease, congestive heart failure, diabetes, depression, hypertension, osteoarthritis, and Stage III and Stage IV/V chronic kidney disease (all p<0.001). Patients with tophi were more likely to be treated with urate-lowering therapy (87.9% vs 72.4%; p<0.001). Of the urate-lowering therapies, patients with tophi were less likely to use allopurinol (52.5% vs 59.0%; p=0.003) and more likely to use febuxostat (28.9% vs 11.0%; p<0.001). Patients with tophi were more likely to use colchicine (40.7% vs 29.2%; p<0.001) and steroids (43.8% vs 18.7%; p<0.001), and less likely to use NSAIDs (35.6% vs 42.9%; p=0.001) for acute flares. Fewer patients with tophi achieved sUA targets of ≤6 mg/dL and no flares (15.7% vs 27.0%; p<0.001) or ≤5 mg/dL and no flares (5.9% vs 12.4%; p<0.001) versus patients without tophi. Patients with tophi made more gout-related office visits (5.18 vs 4.42; p=0.155) and more made ≥1 gout-related emergency visit (26.8% vs 7.9%; p<0.001), hospitalization (12.7% vs 2.2%; p<0.001), or had gout-related surgery (4.4% vs 0.1%; p<0.001) over 12 months.

Conclusion:  Less than 30% of gout patients achieve treatment targets and patients with tophi are less likely to achieve these goals than patients without tophi. Patients with tophi have significantly greater burden of disease and greater frequency of comorbidities than patients without tophi. Preventing development of tophi or resolving crystal burden by treating to guideline targets is an important but rarely achieved goal for patients with and without tophi.


Disclosure: P. Khanna, AstraZeneca, 2; E. Tafesse, AstraZeneca, 3; S. Baumgartner, Ardea Biosciences, a member of the AstraZeneca Group, 3; A. Walker, AstraZeneca, 3; R. Morlock, Ardea Biosciences, 5.

To cite this abstract in AMA style:

Khanna P, Tafesse E, Baumgartner S, Walker A, Morlock R. Comparing the Burden of Illness of Patients with Tophaceous and Non-Tophaceous Gout in France, Germany, Italy, Spain, UK, and USA [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/comparing-the-burden-of-illness-of-patients-with-tophaceous-and-non-tophaceous-gout-in-france-germany-italy-spain-uk-and-usa/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparing-the-burden-of-illness-of-patients-with-tophaceous-and-non-tophaceous-gout-in-france-germany-italy-spain-uk-and-usa/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology